Kwality Pharmaceuticals Ltd · KPL · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 13 November 2026
Kwality Pharmaceuticals share price today: ₹4,207.90 at the close on 18 November 2026, up 345.7% in a year. Kwality Pharmaceuticals (KPL) is worth ₹4,365 crore, trades at a P/E of 45.5 and has closed between ₹895.70 and ₹4,207.90 over the past 52 weeks. Latest change: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare).
Kwality Pharmaceuticals Ltd's share price has risen faster than its earnings: +345.7% in a year, against +95.6% for earnings per share.
The main question: the share price moved +345.7% in a year while earnings per share (last four quarters) moved +95.6%. The difference came from the market paying a higher multiple.
The price has been rising for 47 weeks, and the P/E is higher than 98% of its own last 10 years. Over the last four quarters, results have been improving, with profit +107.1% on a year earlier, and 86% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.
What is the Kwality Pharmaceuticals share price today?
Kwality Pharmaceuticals Ltd's share price was ₹4,207.90 at the close on 18 November 2026. It has been rising for 47 weeks. That is 58.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹896 and ₹4,208, and at that close it was at the high of that range.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Kwality Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.
Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 44 weeks in a row.
Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 260 of 450 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 22 Jul 2016 | no NIFTY 500 reading |
| 29 Jul 2016 | no NIFTY 500 reading |
| 4 Aug 2016 | no NIFTY 500 reading |
| 10 Aug 2016 | no NIFTY 500 reading |
| 26 Aug 2016 | no NIFTY 500 reading |
| 31 Aug 2016 | no NIFTY 500 reading |
| 15 Sep 2016 | no NIFTY 500 reading |
| 21 Sep 2016 | no NIFTY 500 reading |
| 28 Sep 2016 | no NIFTY 500 reading |
| 7 Oct 2016 | no NIFTY 500 reading |
| 10 Oct 2016 | no NIFTY 500 reading |
| 17 Oct 2016 | no NIFTY 500 reading |
| 26 Oct 2016 | no NIFTY 500 reading |
| 3 Nov 2016 | +17.8% |
| 7 Nov 2016 | +23.1% |
| 17 Nov 2016 | +41.1% |
| 2 Dec 2016 | +48.9% |
| 8 Dec 2016 | +61.1% |
| 14 Dec 2016 | +81.2% |
| 23 Dec 2016 | +76.0% |
| 27 Dec 2016 | +70.7% |
| 6 Jan 2017 | +78.0% |
| 12 Jan 2017 | +71.6% |
| 20 Jan 2017 | +80.2% |
| 2 Feb 2017 | +52.7% |
| 14 Feb 2017 | +58.9% |
| 22 Feb 2017 | +65.4% |
| 28 Feb 2017 | +57.2% |
| 6 Mar 2017 | +52.1% |
| 5 Apr 2017 | +43.7% |
| 13 Apr 2017 | +24.4% |
| 4 May 2017 | +7.2% |
| 1 Jun 2017 | +0.2% |
| 9 Jun 2017 | −1.3% |
| 16 Jun 2017 | +3.7% |
| 23 Jun 2017 | −6.8% |
| 30 Jun 2017 | −15.7% |
| 7 Jul 2017 | +3.9% |
| 13 Jul 2017 | +1.1% |
| 21 Jul 2017 | −15.7% |
| 28 Jul 2017 | −17.0% |
| 31 Jul 2017 | −21.0% |
| 10 Aug 2017 | −24.3% |
| 17 Aug 2017 | −24.2% |
| 23 Aug 2017 | −16.6% |
| 1 Sep 2017 | −6.7% |
| 8 Sep 2017 | +5.8% |
| 15 Sep 2017 | −6.1% |
| 22 Sep 2017 | +6.2% |
| 29 Sep 2017 | +2.0% |
| 6 Oct 2017 | −4.1% |
| 12 Oct 2017 | −4.0% |
| 19 Oct 2017 | +13.5% |
| 27 Oct 2017 | +14.1% |
| 3 Nov 2017 | +19.0% |
| 10 Nov 2017 | +38.4% |
| 17 Nov 2017 | +35.8% |
| 24 Nov 2017 | +22.4% |
| 30 Nov 2017 | +25.1% |
| 8 Dec 2017 | +18.3% |
| 14 Dec 2017 | +15.3% |
| 22 Dec 2017 | +13.6% |
| 29 Dec 2017 | +16.8% |
| 5 Jan 2018 | +20.0% |
| 12 Jan 2018 | +34.5% |
| 19 Jan 2018 | +15.3% |
| 25 Jan 2018 | +11.2% |
| 2 Feb 2018 | +6.2% |
| 8 Feb 2018 | −5.7% |
| 16 Feb 2018 | −3.7% |
| 23 Feb 2018 | +4.7% |
| 28 Feb 2018 | −5.3% |
| 9 Mar 2018 | +2.9% |
| 14 Mar 2018 | −2.4% |
| 22 Mar 2018 | −15.0% |
| 28 Mar 2018 | −23.2% |
| 5 Apr 2018 | −26.9% |
| 13 Apr 2018 | −31.9% |
| 20 Apr 2018 | −27.9% |
| 27 Apr 2018 | −17.4% |
| 4 May 2018 | −21.4% |
| 11 May 2018 | −22.7% |
| 18 May 2018 | −13.2% |
| 25 May 2018 | −16.3% |
| 1 Jun 2018 | −19.2% |
| 8 Jun 2018 | −22.6% |
| 15 Jun 2018 | −17.4% |
| 22 Jun 2018 | −1.8% |
| 29 Jun 2018 | +14.9% |
| 6 Jul 2018 | +9.8% |
| 13 Jul 2018 | +10.7% |
| 17 Jul 2018 | +8.8% |
| 27 Jul 2018 | −6.8% |
| 3 Aug 2018 | −5.1% |
| 7 Aug 2018 | −2.1% |
| 24 Aug 2018 | −14.2% |
| 29 Aug 2018 | −16.6% |
| 4 Sep 2018 | −10.2% |
| 28 Sep 2018 | −0.1% |
| 4 Oct 2018 | +9.6% |
| 8 Oct 2018 | +4.0% |
| 15 Oct 2018 | −5.7% |
| 26 Oct 2018 | +10.4% |
| 1 Nov 2018 | +2.7% |
| 6 Nov 2018 | +7.7% |
| 22 Nov 2018 | +26.5% |
| 30 Nov 2018 | +25.5% |
| 7 Dec 2018 | +30.3% |
| 14 Dec 2018 | +34.4% |
| 21 Dec 2018 | +33.5% |
| 2 Jan 2019 | +35.6% |
| 21 Jan 2019 | +13.4% |
| 1 Feb 2019 | +9.8% |
| 8 Feb 2019 | +13.8% |
| 13 Feb 2019 | +23.6% |
| 18 Feb 2019 | +12.4% |
| 14 Mar 2019 | −2.0% |
| 20 Mar 2019 | −4.9% |
| 27 Mar 2019 | −41.5% |
| 3 Apr 2019 | −33.6% |
| 16 Apr 2019 | −36.9% |
| 22 Apr 2019 | −33.4% |
| 9 May 2019 | −32.5% |
| 20 Jun 2019 | −41.5% |
| 5 Jul 2019 | −22.1% |
| 10 Jul 2019 | −21.1% |
| 17 Jul 2019 | −19.6% |
| 29 Aug 2019 | −25.8% |
| 19 Sep 2019 | −35.4% |
| 8 Nov 2019 | −39.2% |
| 11 Nov 2019 | −45.2% |
| 29 Nov 2019 | −38.4% |
| 3 Dec 2019 | −41.7% |
| 16 Dec 2019 | −48.5% |
| 26 Dec 2019 | −40.9% |
| 6 Feb 2020 | −29.3% |
| 19 Feb 2020 | −12.3% |
| 24 Feb 2020 | −33.2% |
| 6 Mar 2020 | −27.6% |
| 9 Mar 2020 | −30.7% |
| 20 Mar 2020 | +5.7% |
| 27 Mar 2020 | −7.4% |
| 1 Apr 2020 | +15.6% |
| 7 Apr 2020 | +33.3% |
| 23 Apr 2020 | +78.8% |
| 26 May 2020 | +69.6% |
| 5 Jun 2020 | +79.5% |
| 11 Jun 2020 | +54.7% |
| 8 Jul 2020 | +26.1% |
| 21 Aug 2020 | +11.4% |
| 26 Aug 2020 | +41.9% |
| 4 Sep 2020 | +96.5% |
| 11 Sep 2020 | +84.1% |
| 15 Sep 2020 | +25.1% |
| 1 Oct 2020 | +84.1% |
| 14 Oct 2020 | +85.0% |
| 21 Oct 2020 | +58.9% |
| 18 Nov 2020 | +13.3% |
| 27 Nov 2020 | +22.4% |
| 10 Dec 2020 | +36.8% |
| 24 Dec 2020 | +27.1% |
| 29 Dec 2020 | +26.2% |
| 7 Jan 2021 | +32.0% |
| 15 Jan 2021 | +19.2% |
| 20 Jan 2021 | −26.5% |
| 29 Jan 2021 | −17.9% |
| 4 Feb 2021 | −27.6% |
| 8 Feb 2021 | −29.8% |
| 17 Feb 2021 | −35.6% |
| 23 Feb 2021 | −22.5% |
| 5 Mar 2021 | −11.7% |
| 12 Mar 2021 | −11.0% |
| 19 Mar 2021 | −23.4% |
| 24 Mar 2021 | −22.6% |
| 31 Mar 2021 | −6.3% |
| 15 Apr 2021 | −3.9% |
| 23 Apr 2021 | −6.1% |
| 30 Apr 2021 | +61.9% |
| 7 May 2021 | +68.0% |
| 14 May 2021 | +77.9% |
| 21 May 2021 | +74.3% |
| 28 May 2021 | +87.4% |
| 4 Jun 2021 | +63.6% |
| 11 Jun 2021 | +70.3% |
| 18 Jun 2021 | +73.8% |
| 25 Jun 2021 | +168.9% |
| 2 Jul 2021 | +266.4% |
| 9 Jul 2021 | +238.5% |
| 16 Jul 2021 | +208.9% |
| 23 Jul 2021 | +240.0% |
| 30 Jul 2021 | +123.6% |
| 6 Aug 2021 | +175.5% |
| 13 Aug 2021 | +262.0% |
| 20 Aug 2021 | +347.4% |
| 27 Aug 2021 | +284.5% |
| 3 Sep 2021 | +311.7% |
| 9 Sep 2021 | +367.4% |
| 17 Sep 2021 | +471.9% |
| 24 Sep 2021 | +361.8% |
| 1 Oct 2021 | +362.9% |
| 6 Oct 2021 | +353.2% |
| 13 Oct 2021 | +326.0% |
| 22 Oct 2021 | +319.0% |
| 29 Oct 2021 | +324.9% |
| 4 Nov 2021 | +199.5% |
| 12 Nov 2021 | +103.6% |
| 18 Nov 2021 | +69.8% |
| 26 Nov 2021 | +73.8% |
| 3 Dec 2021 | +104.7% |
| 10 Dec 2021 | +83.1% |
| 17 Dec 2021 | +33.6% |
| 24 Dec 2021 | +28.3% |
| 31 Dec 2021 | +4.4% |
| 7 Jan 2022 | −11.3% |
| 14 Jan 2022 | −1.6% |
| 21 Jan 2022 | −16.3% |
| 28 Jan 2022 | −33.2% |
| 4 Feb 2022 | −39.7% |
| 11 Feb 2022 | −37.0% |
| 18 Feb 2022 | −37.9% |
| 25 Feb 2022 | −37.8% |
| 4 Mar 2022 | −46.6% |
| 11 Mar 2022 | −49.9% |
| 17 Mar 2022 | −51.0% |
| 25 Mar 2022 | −39.9% |
| 1 Apr 2022 | −34.1% |
| 8 Apr 2022 | −31.3% |
| 13 Apr 2022 | −30.0% |
| 22 Apr 2022 | −27.7% |
| 29 Apr 2022 | −29.6% |
| 6 May 2022 | −12.8% |
| 13 May 2022 | −12.7% |
| 20 May 2022 | −15.3% |
| 27 May 2022 | −3.0% |
| 3 Jun 2022 | −16.2% |
| 10 Jun 2022 | −4.0% |
| 17 Jun 2022 | +0.2% |
| 24 Jun 2022 | −27.1% |
| 1 Jul 2022 | −39.2% |
| 8 Jul 2022 | −35.7% |
| 15 Jul 2022 | −33.5% |
| 22 Jul 2022 | −32.6% |
| 29 Jul 2022 | −33.7% |
| 5 Aug 2022 | −37.4% |
| 12 Aug 2022 | −30.8% |
| 19 Aug 2022 | −30.4% |
| 26 Aug 2022 | −39.7% |
| 2 Sep 2022 | −1.0% |
| 9 Sep 2022 | −3.8% |
| 16 Sep 2022 | +18.7% |
| 23 Sep 2022 | +21.6% |
| 30 Sep 2022 | +26.6% |
| 7 Oct 2022 | +42.9% |
| 14 Oct 2022 | +42.2% |
| 21 Oct 2022 | +17.4% |
| 28 Oct 2022 | +21.5% |
| 4 Nov 2022 | +17.4% |
| 11 Nov 2022 | +11.6% |
| 18 Nov 2022 | +11.4% |
| 25 Nov 2022 | +6.5% |
| 2 Dec 2022 | −18.5% |
| 9 Dec 2022 | −23.2% |
| 16 Dec 2022 | −26.0% |
| 23 Dec 2022 | −5.5% |
| 30 Dec 2022 | −12.5% |
| 6 Jan 2023 | −18.9% |
| 13 Jan 2023 | −20.4% |
| 20 Jan 2023 | −14.8% |
| 27 Jan 2023 | −7.0% |
| 3 Feb 2023 | +1.3% |
| 10 Feb 2023 | +8.7% |
| 17 Feb 2023 | +1.6% |
| 24 Feb 2023 | +8.6% |
| 3 Mar 2023 | +6.1% |
| 10 Mar 2023 | +5.4% |
| 17 Mar 2023 | −8.7% |
| 24 Mar 2023 | −19.2% |
| 31 Mar 2023 | −13.3% |
| 6 Apr 2023 | −12.1% |
| 13 Apr 2023 | −9.3% |
| 21 Apr 2023 | −2.7% |
| 28 Apr 2023 | +4.4% |
| 5 May 2023 | −8.1% |
| 12 May 2023 | −14.8% |
| 19 May 2023 | −11.1% |
| 26 May 2023 | −27.4% |
| 2 Jun 2023 | −18.0% |
| 9 Jun 2023 | −17.7% |
| 16 Jun 2023 | −23.5% |
| 23 Jun 2023 | −16.9% |
| 30 Jun 2023 | −15.9% |
| 7 Jul 2023 | −7.2% |
| 14 Jul 2023 | −7.5% |
| 21 Jul 2023 | −13.3% |
| 28 Jul 2023 | −17.5% |
| 4 Aug 2023 | +5.8% |
| 11 Aug 2023 | +10.2% |
| 18 Aug 2023 | +15.8% |
| 25 Aug 2023 | +39.2% |
| 1 Sep 2023 | +22.8% |
| 8 Sep 2023 | +23.9% |
| 15 Sep 2023 | +31.0% |
| 22 Sep 2023 | +11.1% |
| 29 Sep 2023 | +16.4% |
| 6 Oct 2023 | −6.0% |
| 13 Oct 2023 | +0.7% |
| 20 Oct 2023 | +4.7% |
| 27 Oct 2023 | +0.8% |
| 3 Nov 2023 | −11.8% |
| 12 Nov 2023 | −12.4% |
| 17 Nov 2023 | −15.6% |
| 24 Nov 2023 | −3.0% |
| 1 Dec 2023 | −6.3% |
| 8 Dec 2023 | −12.2% |
| 15 Dec 2023 | −10.3% |
| 22 Dec 2023 | −4.6% |
| 29 Dec 2023 | −2.1% |
| 5 Jan 2024 | +9.0% |
| 12 Jan 2024 | +21.6% |
| 20 Jan 2024 | +27.4% |
| 25 Jan 2024 | +13.0% |
| 2 Feb 2024 | +15.7% |
| 9 Feb 2024 | +23.3% |
| 16 Feb 2024 | +32.7% |
| 23 Feb 2024 | +16.1% |
| 2 Mar 2024 | +19.6% |
| 7 Mar 2024 | +20.5% |
| 15 Mar 2024 | +13.0% |
| 22 Mar 2024 | +8.2% |
| 28 Mar 2024 | −1.9% |
| 5 Apr 2024 | +13.4% |
| 12 Apr 2024 | −6.9% |
| 19 Apr 2024 | −11.7% |
| 26 Apr 2024 | +7.0% |
| 3 May 2024 | +4.3% |
| 10 May 2024 | +4.0% |
| 18 May 2024 | −3.4% |
| 24 May 2024 | −1.3% |
| 31 May 2024 | +4.7% |
| 7 Jun 2024 | +8.0% |
| 14 Jun 2024 | +9.6% |
| 21 Jun 2024 | +12.5% |
| 28 Jun 2024 | +8.4% |
| 5 Jul 2024 | −5.0% |
| 12 Jul 2024 | −4.2% |
| 19 Jul 2024 | −0.8% |
| 26 Jul 2024 | −8.4% |
| 2 Aug 2024 | −7.2% |
| 9 Aug 2024 | −7.1% |
| 16 Aug 2024 | +4.3% |
| 23 Aug 2024 | +26.2% |
| 30 Aug 2024 | +24.1% |
| 6 Sep 2024 | +34.0% |
| 13 Sep 2024 | +48.6% |
| 20 Sep 2024 | +39.5% |
| 27 Sep 2024 | +51.8% |
| 4 Oct 2024 | +49.0% |
| 11 Oct 2024 | +57.6% |
| 18 Oct 2024 | +59.7% |
| 25 Oct 2024 | +44.7% |
| 1 Nov 2024 | +85.6% |
| 8 Nov 2024 | +75.9% |
| 14 Nov 2024 | +59.1% |
| 22 Nov 2024 | +24.9% |
| 29 Nov 2024 | +24.5% |
| 6 Dec 2024 | +14.0% |
| 13 Dec 2024 | +2.1% |
| 20 Dec 2024 | +16.1% |
| 27 Dec 2024 | +21.4% |
| 3 Jan 2025 | +23.8% |
| 10 Jan 2025 | +29.8% |
| 17 Jan 2025 | +17.6% |
| 24 Jan 2025 | +22.4% |
| 1 Feb 2025 | −5.7% |
| 7 Feb 2025 | −8.2% |
| 14 Feb 2025 | −9.1% |
| 21 Feb 2025 | −11.8% |
| 28 Feb 2025 | −15.1% |
| 7 Mar 2025 | −8.5% |
| 13 Mar 2025 | −5.5% |
| 21 Mar 2025 | −15.3% |
| 28 Mar 2025 | +2.7% |
| 4 Apr 2025 | −1.9% |
| 11 Apr 2025 | −13.3% |
| 17 Apr 2025 | −8.9% |
| 25 Apr 2025 | −15.8% |
| 2 May 2025 | −16.9% |
| 9 May 2025 | −11.3% |
| 16 May 2025 | −3.8% |
| 23 May 2025 | +24.7% |
| 30 May 2025 | +21.7% |
| 6 Jun 2025 | +17.9% |
| 13 Jun 2025 | +38.2% |
| 20 Jun 2025 | +42.7% |
| 27 Jun 2025 | +6.1% |
| 4 Jul 2025 | +28.8% |
| 11 Jul 2025 | +37.1% |
| 18 Jul 2025 | +35.8% |
| 25 Jul 2025 | +50.3% |
| 1 Aug 2025 | +55.0% |
| 8 Aug 2025 | +54.1% |
| 14 Aug 2025 | +33.0% |
| 22 Aug 2025 | +6.3% |
| 29 Aug 2025 | +12.7% |
| 5 Sep 2025 | +2.6% |
| 12 Sep 2025 | −5.2% |
| 19 Sep 2025 | −9.1% |
| 26 Sep 2025 | −7.2% |
| 3 Oct 2025 | −20.0% |
| 10 Oct 2025 | −26.8% |
| 17 Oct 2025 | −26.9% |
| 24 Oct 2025 | −24.6% |
| 31 Oct 2025 | −25.1% |
| 7 Nov 2025 | −28.9% |
| 14 Nov 2025 | −15.5% |
| 21 Nov 2025 | −10.3% |
| 28 Nov 2025 | −12.5% |
| 5 Dec 2025 | −8.9% |
| 12 Dec 2025 | −4.6% |
| 19 Dec 2025 | +6.3% |
| 26 Dec 2025 | +17.3% |
| 2 Jan 2026 | +16.1% |
| 9 Jan 2026 | +31.8% |
| 16 Jan 2026 | +26.4% |
| 23 Jan 2026 | +25.4% |
| 1 Feb 2026 | +21.1% |
| 6 Feb 2026 | +35.1% |
| 13 Feb 2026 | +51.6% |
| 20 Feb 2026 | +52.6% |
| 27 Feb 2026 | +70.2% |
| 6 Mar 2026 | +67.6% |
| 17 Apr 2026 | +84.6% |
| 24 Apr 2026 | +63.1% |
| 30 Apr 2026 | +48.2% |
| 8 May 2026 | +62.6% |
| 15 May 2026 | +53.1% |
| 22 May 2026 | +99.0% |
| 29 May 2026 | +108.4% |
| 5 Jun 2026 | +128.9% |
| 3 Jul 2026 | +131.7% |
| 10 Jul 2026 | +81.2% |
| 17 Jul 2026 | +89.7% |
| 24 Jul 2026 | +79.6% |
| 31 Jul 2026 | +73.9% |
| 7 Aug 2026 | +45.7% |
| 14 Aug 2026 | +107.3% |
| 18 Aug 2026 | +119.4% |
| 21 Aug 2026 | +89.9% |
| 28 Aug 2026 | +88.1% |
| 4 Sep 2026 | +51.6% |
| 11 Sep 2026 | +56.7% |
| 18 Sep 2026 | +43.4% |
| 25 Sep 2026 | +40.2% |
| 28 Sep 2026 | +42.6% |
| 1 Oct 2026 | +38.4% |
| 9 Oct 2026 | +32.9% |
| 16 Oct 2026 | +36.7% |
| 23 Oct 2026 | +44.9% |
| 30 Oct 2026 | +8.1% |
| 6 Nov 2026 | +3.6% |
| 8 Nov 2026 | +10.1% |
| 13 Nov 2026 | +14.6% |
| 18 Nov 2026 | +25.7% |
Over the last 10 years the share price moved +18,602% while the NIFTY 500 moved +228%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Kwality Pharmaceuticals this quarter?
Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), best operating margin in 15 quarters and profit up on a year earlier for 10 quarters in a row.
Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)
In the September 2026 quarter revenue was ₹181 crore, +63.1% on a year earlier.
Best operating margin in 15 quarters
Operating margin was 27% in the September 2026 quarter, against 23% a year earlier.
Profit up on a year earlier for 10 quarters in a row
In the September 2026 quarter profit was ₹29 crore, +107.1% on a year earlier.
What are Kwality Pharmaceuticals' latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Kwality Pharmaceuticals reported revenue of ₹181 crore, up 63.1% from ₹111 crore a year earlier, and a profit of ₹29.0 crore, up 107.1% from ₹14.0 crore.
Kwality Pharmaceuticals results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹181 crore | ₹111 crore | +63.1% |
| Profit | ₹29.0 crore | ₹14.0 crore | +107.1% |
| Earnings per share | ₹27.98 | ₹13.61 | +105.6% |
| Operating margin | 27.6% | 22.5% | +5.1 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Kwality Pharmaceuticals' management discussed these results on a call held on 13 November 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Kwality Pharmaceuticals share price history?
Kwality Pharmaceuticals closed at ₹4,207.90 on 18 November 2026, up 345.7% from ₹944.10 a year earlier (21 November 2025) and up 412.1% over five years. Its highest weekly close since July 2016 was ₹4,207.90 on 18 November 2026.
Kwality Pharmaceuticals share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹3,983.80 | +5.6% |
| 1 month ago · 19 Oct 2026 | ₹3,366.00 | +25.0% |
| 6 months ago · 15 May 2026 | ₹1,719.20 | +144.8% |
| 1 year ago · 21 Nov 2025 | ₹944.10 | +345.7% |
| 3 years ago · 17 Nov 2023 | ₹340.70 | +1,135.1% |
| 5 years ago · 18 Nov 2021 | ₹821.75 | +412.1% |
| 10 years ago · 17 Nov 2016 | ₹29.35 | +14,237.0% |
| Earliest weekly close in our records · 22 Jul 2016 | ₹22.50 | +18,601.8% |
| Highest weekly close since July 2016, also the 52-week high · 18 Nov 2026 | ₹4,207.90 | 0.0% |
| Lowest weekly close since July 2016 · 16 Dec 2019 | ₹21.30 | +19,655.4% |
| 52-week low (weekly close) · 5 Dec 2025 | ₹895.70 | +369.8% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
463 weekly closes from 22 July 2016 to 18 November 2026.
What is the latest news on Kwality Pharmaceuticals?
18 Nov 2026: Kwality Pharmaceuticals closed at ₹4,207.90, up 5.6% on the week and up 25.0% on the month. 13 Nov 2026: Kwality Pharmaceuticals held its results call for July to September 2026.
Earlier
- Results for July to September 2026: Revenue up 63.1% and profit up 107.1% on a year earlier.
What dividend does Kwality Pharmaceuticals pay?
Kwality Pharmaceuticals has paid no dividend on the exchange since 1 April 2021, the start of the period we checked.
Not in its latest year. Kwality Pharmaceuticals Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 13 reported years, so there is a history but no current dividend.
From the exchange corporate-actions record, read 18 November 2026.
What did Kwality Pharmaceuticals management say on the latest results call?
On the call for July to September 2026, held on 13 November 2026, Kwality Pharmaceuticals' management spoke about the quarter; the main points are below.
Source: the call transcript.
From the call for July to September 2026, 13 November 2026.
What to watch in Kwality Pharmaceuticals' next results?
When Kwality Pharmaceuticals reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier.
- Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was +63.1% on a year earlier, and the last four quarters averaged +47.7%.
- Whether the operating margin stays near 27.6%. It is 5.1 percentage points higher than four quarters earlier.
- Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +107.1% on a year earlier. It has grown on a year earlier for 10 quarters in a row.
Which stock lists is Kwality Pharmaceuticals on?
Kwality Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks.
Is Kwality Pharmaceuticals profitable?
Kwality Pharmaceuticals Ltd earned ₹29.0 Cr of net profit in the Sep 2026 quarter, +107.1% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹67.0 Cr. Over 10 years profit has grown 52.3% a year on average. The same quarter a year earlier earned ₹14.0 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Sep 2026 quarter's profit is 16.0% of that quarter's revenue.
For the full year, FY26 profit was ₹67.0 Cr (+67.5% on the year before).
Why profit moved: revenue changed +63.1% on a year earlier and the margin moved +5.1 percentage points. Most of the change came from keeping more of each sale.
On average over the last four quarters, profit changed +95.0% and revenue +47.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.
How much revenue does Kwality Pharmaceuticals make, and is it growing?
Kwality Pharmaceuticals Ltd reported ₹181 Cr of revenue in the Sep 2026 quarter, +63.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 21.1% a year on average. The last full year, FY26, came in at ₹503 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. The near-term revenue driver. Regulated export markets carry 2-3× the realization of domestic generics. Management's H1 FY26 baseline is ₹60-70 Cr from these three markets; the FY27 guide is ₹200 Cr incremental (implying ₹260-270 Cr from these markets alone in FY27). The 40+ bioequivalence programs and 400-500 out-licensed molecules across 30-40 countries build the long-term distribution moat. The short-term proof point is whether Q1 FY27 revenue shows the ₹50 Cr+ run-rate from these geographies.
The last four reported quarters add to ₹623 Cr.
FY26 revenue was ₹503 Cr, +35.9% on the year before.
Recent pace: the last four quarters grew +47.7% on average, against 21.1% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +47.6%, against +35.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +95.9%, against +85.2% a year (accelerating).
Watch next
- Metric
- Geographical Expansion, Regulated Markets (Mexico…
- Threshold
- Q1 FY27 revenue vs ₹140-150 Cr goal; Unit 5 hormone plant CWIP in balance sheet
- Which result
- the next result
How much of every ₹100 of sales does Kwality Pharmaceuticals keep?
Kwality Pharmaceuticals Ltd's operating margin was 27.6% in the Sep 2026 quarter, 5.1 percentage points higher than the same quarter a year ago. Across 13 years it has been between 5.8% and 37.7%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why this happened. The core driver. Kwality's move to regulated markets (EU-GMP, PIC/S certified) unlocks higher pricing on the same manufacturing base. The OPM expansion from 21% to 24% reflects both mix shift (regulated export premium) and operating leverage on fixed cost. The FY27 guide of 25-26% EBITDA implies another 100-200bps of expansion, supported by biosimilar/biologic mix shift, which carries structurally higher margins than commodity generics. The revenue trajectory is the cleanest signal: 4 consecutive acceleration quarters, with Dec 2025 quarter at ₹123 Cr vs Dec 2024 ₹84 Cr (+46.4% YoY).
Why the margin moved: operating margin changed +4.7 percentage points on the year while gross margin changed +1.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.
Watch next
- Metric
- Operating Leverage Inflection
- Threshold
- Q1 FY27 revenue vs ₹140-150 Cr goal; Unit 5 hormone plant CWIP in balance sheet
- Which result
- the next result
Is Kwality Pharmaceuticals' profit turning into cash?
Over the last 3 years, 86% of Kwality Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹17.0 Cr of operating cash against ₹67.0 Cr of profit.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
After ₹45.0 Cr of spending on assets, free cash was −₹28.0 Cr: it spent more than its operations brought in.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 86% of profit came in as cash: the cash cycle got 140 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.
What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building.
Where does Kwality Pharmaceuticals' cash go?
Kwality Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 170 days in FY26, up from 30 days in FY21. It spent ₹98.0 Cr on assets over the last 3 years. Customers take 203 days to pay, and stock sits for 111 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹503 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly ₹234 Cr is tied up in the business at any time.
FY26: customers took 203 days to pay and stock sat for 111 days, about 3.7 months of sales sitting as stock, for a full cycle of 170 days, longer than FY21's 30.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 111 days. Customers pay about 203 days after that. Suppliers are paid at 144 days. Together that makes the 170-day cycle.
Spending on assets: ₹98.0 Cr over the last 3 years, against ₹58.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹17.0 Cr (FY26): assets paid for that are not earning yet.
In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.
What is Kwality Pharmaceuticals' P/E ratio, and how does it compare with its own history?
Kwality Pharmaceuticals Ltd's P/E is 45.5×, about the highest it has ever been. Its usual P/E (the middle reading) is 15.8×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why the multiple is where it is: over the past year earnings per share moved +95.6% while the price moved +345.7%. The price did better than earnings, which pushed the multiple up within its own range.
Where the price move came from: over 3 years the price moved +131.2% a year; about +105.3% a year came from earnings growth and about +25.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.
Is the Kwality Pharmaceuticals business getting better or worse?
Kwality Pharmaceuticals Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 30.3% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: steady growth with healthy returns is how a business compounds over time.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +35.9% | +26.1% | +13.9% | +21.1% |
| Profit | +67.5% | +52.2% | +34.9% | +52.3% |
| EPS | +69.0% | +51.5% | +34.8% | +45.3% |
| Share price | +345.7% | +131.2% | +38.6% | +64.3% |
What is the Kwality Pharmaceuticals story, and has it been checked?
Kwality Pharmaceuticals Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: fully expanded. Still open: Revenue miss (₹124 vs ₹140 Cr), Unit 6 CWIP=0 contradiction, US market strategic pivot, Africa subsidiary exit, all surfaced in a single Feb 2026 concall.
NOT YET CHECKED
Our read, 17 May 2026. A commodity-generics formulator mid-leap into regulated-market exports and biologics, 4-quarter momentum validates the move; management credibility under watch.
From the price. Price stage 2, week 47, above its 200-day line, relative strength falling.
Where they disagree. The current reading at 24.45 is approaching the 2017 peak level. EPS trajectory is the positive counter: ₹11.50 → ₹13.61 → ₹15.43 across Q1-Q3 FY26.
What is not proven yet. Revenue miss (₹124 vs ₹140 Cr), Unit 6 CWIP=0 contradiction, US market strategic pivot, Africa subsidiary exit, all surfaced in a single Feb 2026 concall.
The test written in advance. Management credibility, 4 documented consistency failures. Measured by: Management credibility, 4 documented consistency failures Q1 FY27 revenue vs ₹140-150 Cr goal; Unit 5 hormone plant CWIP in balance sheet by the next result.
The test written in advance. OPM vs 24% Dec quarter benchmark by the next result.
The test written in advance. Biologic execution, first-time EPO launch risk. Measured by: Biologic execution, first-time EPO launch risk Clinical trial commencement April 2027; interim export announcement H1 FY27 by the next result.
What the company does. Revenue accelerated 4 consecutive quarters (YoY: +26%, +39%, +23%, +46%), OPM expanded from 21% to 24%, TTM PAT +93%, the inflection is real. Management's FY27 PAT goal of ₹100 Cr (vs TTM ~₹56 Cr) is bold; Erythropoietin biologic launch and Mexico/Colombia registrations are the next proof points.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters |
|---|---|---|
| Operating Leverage Inflection | HIGH | Revenue +26/39/23/46% YoY over 4 quarters; OPM 21→22→23→24%, operating leverage converting revenue growth to PAT +93% TTM. |
| Biologic Launch, Erythropoietin (EPO) | HIGH | First biologic launch, EPO pre-clinical approved, clinical trials April 2027, interim export H1 FY27; biologic mix structurally… |
| Geographical Expansion, Regulated Markets… | HIGH | Mexico/Colombia/Algeria registrations moving to commercialization, management guides ₹200 Cr incremental FY27 from these 3… |
| Working Capital Normalization | MEDIUM | CCC goal 170-180 days from ~280 days, inventory optimization and mix shift to higher-paying markets (Mexico/Colombia)… |
| Specialty Manufacturing Build-Out… | MEDIUM | Oncology Unit 3 at 65-70% utilization expanding; 5 CDMO molecules with European partners; Hormones Unit 5 (₹60 Cr) aiming for… |
Everything further down this page is evidence for or against these.
FY25-Q4FY26-Q3
- 1 · Operating leveragebuilding
- 2 · Value-added mixquiet
- 3 · Management changequiet
- 4 · Paying down debtquiet
- 5 · Regulatory approvalbuilding
- 6 · Order-book winsquiet
- 7 · Consolidationbuilding
- 8 · Demerger or value unlockquiet
- 9 · Buybackquiet
- 10 · New geographiesbuilding
- 11 · More business from existing customersbuilding
- 12 · New product launchquiet
- 13 · Mandatory normsquiet
- 14 · A bigger market to servequiet
- 15 · Market-share gainsquiet
- 16 · Asset qualityquiet
Lever 1 · Operating leverage: building. Revenue +26/39/23/46% YoY over 4 quarters; OPM 21→22→23→24%, operating leverage converting revenue growth to PAT +93% TTM. What proves it keeps working: Operating Leverage Inflection. It stops working if Q1 FY27 revenue vs ₹140-150 Cr goal; Unit 5 hormone plant CWIP in balance sheet.
Lever 5 · Regulatory approval: building. First biologic launch, EPO pre-clinical approved, clinical trials April 2027, interim export H1 FY27; biologic mix structurally expands OPM to 29-30% by FY29. What proves it keeps working: Biologic Launch, Erythropoietin (EPO).
Lever 10 · New geographies: building. Mexico/Colombia/Algeria registrations moving to commercialization, management guides ₹200 Cr incremental FY27 from these 3 markets alone (vs H1 FY26 baseline of ₹60-70 Cr from all 3 combined). What proves it keeps working: Geographical Expansion, Regulated Markets (Mexico, Colombia, Algeria).
Lever 7 · Consolidation: building. CCC goal 170-180 days from ~280 days, inventory optimization and mix shift to higher-paying markets (Mexico/Colombia) releasing capital; ROCE trajectory improving. What proves it keeps working: Working Capital Normalization.
Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
Did Kwality Pharmaceuticals management deliver what it promised?
What Kwality Pharmaceuticals Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
EPO Regulatory Pathway Reversed · 13 November 2026. In Aug 2026, management said the Erythropoietin dossier could lead to registrations in 10-12 ROW countries after the first four-month study, without waiting for complete clinical trials. In Nov 2026, management said formal registration is subject to clinical studies and only temporary supplies may be made under a biowaiver. This changes the regulatory basis and timing of the EPO revenue case, rather than merely refining the launch schedule.
BE Program FY29 Revenue Estimate Cut · 13 November 2026. In Aug 2026, management projected at least INR400 crores to INR500 crores of FY29 revenue from the BE program. In Nov 2026, management instead described FY29 revenue of only 250-300 crores for the product group discussed, despite the earlier 40-BE program scope. The latest call does not reconcile this materially lower estimate with the prior program assumptions.
Debtor-Day Progress Reversed · 13 November 2026. In Aug 2026, management expected debtor days to settle at 165-170 days and planned 155-160 days in regular operations. In Nov 2026, management reported debtor days of 178 days, above both the prior current range and the stated operating goal. Although the latest call described the overall working capital cycle as improved and said Middle East receivables had been realized, it did not explain why debtor days moved away from the earlier goal.
Saudi and GCC Growth Thesis Deprioritized · 13 November 2026. In Aug 2026, management positioned Saudi Arabia and the broader GCC as the next geographic growth venue, with revenue expected by the end of the third quarter. In Nov 2026, management said Saudi Arabia, Iraq, and Iran were slow-moving and were no longer a significant focus, shifting future emphasis to Latin America and Europe. Although slow-moving markets were cited as the reason, management did not reconcile this strategic reversal with the earlier expected Saudi and GCC revenue ramp.
Every quote above is taken word for word from the company’s own earnings calls.
How much does Kwality Pharmaceuticals earn on its capital?
Kwality Pharmaceuticals Ltd earned a ROCE of 24% in FY26. That is up from a low of 9% in FY15. Its return on capital used (ROIC) is 9.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.3% net margin and 0.85× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 13.3% net margin × 0.85× asset turnover × 1.79× leverage (assets divided by equity) ≈ 20.2% on equity. The margin does its share; borrowing is a big part of it.
The key test, return on capital used minus the cost of capital: 21.2% − 12.0% = +9.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 21.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 18.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does Kwality Pharmaceuticals have too much debt?
Kwality Pharmaceuticals Ltd has total debt of ₹146 Cr against shareholder equity of ₹386 Cr as of Sep 2026, so its debt is 0.38× its equity. Year by year, that ratio went from 0.35 in FY22 to 0.40 in FY26. Keep that borrowing in mind when reading the returns on this page.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
What is the Kwality Pharmaceuticals shareholding pattern?
Foreign institutions raised their stake in Kwality Pharmaceuticals Ltd by 2.5 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.5% of the company. Domestic institutions moved +1.1 points over the same period, to 1.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Over the last two years: Foreign institutions: +2.5 points over 8 quarters, to 2.5%; Domestic institutions: +1.1 points over 8 quarters, to 1.1%; Promoters: +0.0 points over 8 quarters, to 54.9%.
Why the owners changed: foreign institutions drove it (+2.5 points), together with domestic institutions (+1.1 points). They raised their stake step by step.
How far is Kwality Pharmaceuticals from balance-sheet trouble?
For Kwality Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
Why this happened. The strategic step-change catalyst. EPO (Erythropoietin) is the company's first biosimilar, with a clear regulatory pathway: interim export beginning June-July 2027, India commercialization August 2027. Management's guide to 40+ bioequivalence programs and five CDMO partnerships with European innovators creates a pipeline overlay. The biologic thesis is incremental margin, not incremental volume, a single biologic molecule in the oncology/biosimilar segment can contribute at 35-40% gross margin vs the 24% current blended OPM. This is the driver underpinning the FY29 margin guide of 29-30%. Risk: first-time biologics execution, regulatory approval uncertainty, clinical trial timeline.
Watch next
- Metric
- Biologic Launch, Erythropoietin (EPO)
- Threshold
- Q1 FY27 revenue vs ₹140-150 Cr goal; Unit 5 hormone plant CWIP in balance sheet
- Which result
- the next result
How does Kwality Pharmaceuticals rank in its industry?
68.3 out of 100, rank 3 of 44 in Pharma - Formulators, with 75% of the evidence available.
Kwality Pharmaceuticals Ltd scores 68.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 3. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
The four parts add up to the total exactly: 32.5 + 17 + 6.5 + 12.3 = 68.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Kwality Pharmaceuticals compared with?
Kwality Pharmaceuticals ranks 3 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 68.3 out of 100.
- 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100
How the score adds up
Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Kwality Pharmaceuticals Ltd this pageKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100
How the score adds up
Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100
How the score adds up
Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100
How the score adds up
Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. - 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100
How the score adds up
Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100
How the score adds up
Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100
How the score adds up
Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100
- 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100
- 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100
- 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100
- 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100
- 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100
- 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100
- 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100
- 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100
- 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100
- 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100
- 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100
- 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100
- 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100
- 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100
- 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100
- 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100
- 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100
- 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100
- 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100
- 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100
- 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100
- 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100
- 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100
- 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100
- 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100
- 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100
- 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100
- 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to Kwality Pharmaceuticals in size?
Kwality Pharmaceuticals is the 29th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Suven Life Sciences, Bliss GVS Pharma and FDC. Just below it: Gufic BioSciences, RPG Life Sciences and Fredun Pharmaceuticals.
Pharma - Formulators companies close in size
- Suven Life Sciences Ltd ₹7,507 crore
- Bliss GVS Pharma Ltd ₹7,238 crore
- FDC Ltd ₹6,087 crore
- Kwality Pharmaceuticals Ltd ₹4,366 crore
- Gufic BioSciences Ltd ₹4,235 crore
- RPG Life Sciences Ltd ₹4,139 crore
- Fredun Pharmaceuticals Ltd ₹2,802 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- West Coast Paper Mills Ltd ₹4,380 crore · Paper
- V-Marc India Ltd ₹4,372 crore · Cables - Power
- Kwality Pharmaceuticals Ltd ₹4,366 crore
- Saatvik Green Energy Ltd ₹4,357 crore · Electric Equipment - General
- Juniper Hotels Ltd ₹4,335 crore · Hotels
What else do people ask about Kwality Pharmaceuticals?
What is Kwality Pharmaceuticals's share price today?
Kwality Pharmaceuticals Ltd's share price is ₹4,207.90, +345.7% over the past year. The whole company is worth ₹4,365 Cr on the market. It is at its highest price of the past 52 weeks (range ₹896 to ₹4,208), 58.3% above its 200-day average.
The price has been rising for 47 weeks (as of 18 November 2026).
What were Kwality Pharmaceuticals's latest quarterly results?
Kwality Pharmaceuticals Ltd reported revenue of ₹181 Cr and net profit of ₹29.0 Cr for the Sep 2026 quarter. Revenue rose 63.1% and profit rose 107.1% compared with a year earlier. Earnings per share were ₹27.98.
The operating margin was 27.6%, 5.1 percentage points higher than a year earlier (as of 18 November 2026).
What is Kwality Pharmaceuticals's market cap?
Kwality Pharmaceuticals Ltd's market capitalisation is ₹4,365 Cr at a share price of ₹4,207.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Kwality Pharmaceuticals performing?
Kwality Pharmaceuticals Ltd's share price has been rising for 47 weeks. In its latest quarter, revenue rose 63.1% and profit rose 107.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 44 weeks running (as of 18 November 2026).
Will Kwality Pharmaceuticals's share price go up?
This page does not forecast Kwality Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹4,207.90, and it has been rising for 47 weeks. Its P/E of 45.5× is higher than 98% of its own last 10 years (as of 18 November 2026).
Who owns Kwality Pharmaceuticals?
Promoters own 54.9% of Kwality Pharmaceuticals Ltd, foreign institutions 2.5%, domestic institutions 1.1% and the public 41.6% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 2.5 percentage points over 8 quarters (as of 18 November 2026).
Where is Kwality Pharmaceuticals in its business cycle?
Kwality Pharmaceuticals Ltd's FY26 operating margin was 23.5%, against a 13-year range of 5.8% to 37.7%. The latest quarter was 27.6%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Kwality Pharmaceuticals story?
The main question: the share price moved +345.7% in a year while earnings per share (last four quarters) moved +95.6%. The difference came from the market paying a higher multiple.
On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Kwality Pharmaceuticals a stock worth studying right now?
What the numbers show: Kwality Pharmaceuticals Ltd's share price has risen faster than its earnings: +345.7% in a year, against +95.6% for earnings per share. The main open question: whether earnings grow into a price that has already moved.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.